| Literature DB >> 30734113 |
Guilherme D Kolinger1, David Vállez García1, Gerbrand M Kramer2, Virginie Frings2, Egbert F Smit3,4, Adrianus J de Langen3,4, Rudi A J O Dierckx1, Otto S Hoekstra2, Ronald Boellaard5,6.
Abstract
BACKGROUND: Total metabolic active tumour volume (TMATV) and total tumour burden (TTB) are increasingly studied as prognostic and predictive factors in non-small cell lung cancer (NSCLC) patients. In this study, we investigated the repeatability of TMATV and TTB as function of uptake interval, positron emission tomography/computed tomography (PET/CT) image reconstruction settings, and lesion delineation method. We used six lesion delineation methods, four direct PET image-derived delineations and two based on a majority vote approach, i.e. intersection between two or more delineations (MV2) and between three or more delineations (MV3). To evaluate the accuracy of those methods, they were compared with a reference delineation obtained from the consensus of the segmentations performed by three experienced observers. Ten NSCLC patients underwent two baseline whole-body [18F]2-Fluoro-2-deoxy-2-D-glucose ([18F]FDG) PET/CT studies on separate days, within 3 days. Two scans were obtained on each day at 60 and 90 min post-injection to assess the influence of tracer uptake interval. PET/CT images were reconstructed following the European Association of Nuclear Medicine Research Ltd. (EARL) compliant settings and with point-spread-function (PSF) modelling. Repeatability between the measurements of each day was determined and the influence of uptake interval, reconstruction settings, and lesion delineation method was assessed using the generalized estimating equations model.Entities:
Keywords: FDG PET/CT; Majority vote; Metabolic active tumour volume; NSCLC; Repeatability; Total tumour burden; Tracer uptake interval; Tumour delineation
Year: 2019 PMID: 30734113 PMCID: PMC6367490 DOI: 10.1186/s13550-019-0481-1
Source DB: PubMed Journal: EJNMMI Res ISSN: 2191-219X Impact factor: 3.138
Patient demographics and scan characteristics
| Characteristic | Overall | Scans at day 1 | Scans at day 2 |
|---|---|---|---|
| Patients | 10 | ||
| Gender ratio (M/F) | 1.5 | ||
| Age (years) | 61 [45–66] | ||
| Stage | |||
| IIIB | 3 | ||
| IV | 7 | ||
| Histology | |||
| Adenocarcinoma | 7 | ||
| Squamous cell carcinoma | 3 | ||
| Weight (kg) | 76 [57–110] | 75 [57–113] | |
| Injected activity (MBq) | 248 [194–377] | 238 [192–392] | |
| Scan start time (min) | |||
| Uptake time goal of 60 min | 61 [59–67] | 60 [60–63] | |
| Uptake time goal of 90 min | 92 [90–97] | 90 [90–95] | |
Fig. 1Box plots with median and range of TMATV (left panel) and TTB (right panel). Both panels show data from the delineations in images acquired at the first and second day of scans, indicated by the colours. Images were acquired 60 min post-injection and reconstructed following EARL compliant settings. TMATV in milliliter and TTB in grams
Fig. 2Box plots with median and range of TMATV (mL). Y-axis in log-10 scale for better visualisation; outliers included. Panels on the left show the values acquired from EARL compliant reconstruction by the six semi-automatic delineation methods as well as the reference delineation (horizontal axis). On the right panels, data from images with PSF reconstruction. On the top row, data from the test (day 1 of scans) is displayed, while on the bottom row from retest (day 2 of scans). Data from scans acquired 60 or 90 min post-injection are colour-coded
Fig. 3Jaccard index for all patients delineated with the semi-automatic delineation methods (when compared against RD) for day 1 (left panel) and day 2 (right panel). Each patient is displayed with a different symbol
Jaccard index and interquartile range
| Delineation method | Day 1 | Day 2 | ||
|---|---|---|---|---|
| Average JI | Interquartile range | Average JI | Interquartile range | |
| SUV25 | 0.62 | [0.48–0.73] | 0.55 | [0.39–0.72] |
| SUV40 | 0.62 | [0.54–0.77] | 0.59 | [0.46–0.80] |
| 41MAX | 0.65 | [0.45–0.88] | 0.64 | [0.45–0.85] |
| A50P | 0.50 | [0.37–0.65] | 0.50 | [0.35–0.67] |
| MV2 | 0.71 | [0.61–0.80] | 0.70 | [0.54–0.86] |
| MV3 | 0.58 | [0.39–0.77] | 0.56 | [0.40–0.79] |
Average Jaccard index and the interquartile range of each semi-automatic delineation method. JI with the reference delineation of each day, RD1 and RD2, respectively. For scans acquired 60 min after injection and reconstructed following EARL compliant settings
Repeatability of experienced observers and reference delineation
| Observer | TMATV | TTB | ||||
|---|---|---|---|---|---|---|
| TRT (RC) | TRT% (RC%) | ICC | TRT (RC) | TRT% (RC%) | ICC | |
| AB | 4.2 (98) | 1.6 (53) | 0.95 | 83 (426) | 3.2 (37) | 0.99 |
| RB | 4.6 (73) | 2.5 (76) | 0.97 | 94 (631) | − 0.5 (54) | 0.98 |
| WN | − 43.7 (161) | − 28.6 (86) | 0.79 | − 121 (648) | − 19.1 (66) | 0.98 |
| RD | − 5.7 (82) | − 9.8 (61) | 0.96 | 41 (505) | − 4.6 (43) | 0.99 |
Average repeatability and repeatability coefficient and corresponding ICC of total metabolic active tumour volume (TMATV) and total tumour burden (TTB) for the three experienced observers and the reference delineation. TRT in mL and TRT% in percentage
Fig. 4Box plots of TMATV (left panel) and TTB (right panel) repeatability from the three experienced observers and their consensus, RD
Total metabolic active tumour volume repeatability for different tracer uptake intervals, reconstruction settings, and lesion delineation methods
| Method | 60 min of uptake | 90 min of uptake | ||||
|---|---|---|---|---|---|---|
| TRT (RC) | TRT% (RC%) | ICC | TRT (RC) | TRT% (RC%) | ICC | |
| EARL | ||||||
| SUV25 | 29.7 (211) | 5.9 (51) | 0.93 | 9.4 (35) | 3.7 (15) | 1.00 |
| SUV40 | 2.5 (44) | 1.0 (31) | 0.99 | 3.5 (17) | 7.9 (32) | 1.00 |
| 41MAX | 4.5 (35) | 7.8 (45) | 0.99 | 6.5 (30) | 3.0 (14) | 1.00 |
| A50P | 0.4 (38) | 5.9 (49) | 0.92 | 16.2 (77) | 10.5 (37) | 0.83 |
| MV2 | 9.4 (48) | 9.3 (44) | 0.99 | 5.4 (24) | 3.5 (15) | 1.00 |
| MV3 | − 4.2 (36) | 1.2 (39) | 0.94 | 15.7 (78) | 9.1 (38) | 0.83 |
| RD | − 5.7 (82) | − 9.8 (61) | 0.96 | |||
| PSF | ||||||
| SUV25 | 46.0 (171) | 14.9 (44) | 0.95 | 139.5 (738) | 14.4 (63) | 0.65 |
| SUV40 | 3.4 (23) | 1.8 (29) | 1.00 | 3.8 (19) | 5.6 (22) | 1.00 |
| 41MAX | 3.2 (17) | 6.9 (35) | 1.00 | 17.4 (92) | 6.2 (30) | 0.92 |
| A50P | 2.1 (15) | 0.2 (19) | 0.99 | 5.7 (19) | 8.2 (21) | 0.98 |
| MV2 | 5.4 (25) | 3.0 (35) | 1.00 | 14.5 (75) | 5.6 (22) | 0.98 |
| MV3 | 2.8 (14) | 3.1 (18) | 1.00 | 3.7 (20) | 3.9 (21) | 0.98 |
Average and repeatability coefficient of total metabolic active tumour volume (TMATV) repeatability for different tracer uptake intervals, reconstruction settings, and lesion delineation methods, including the corresponding ICC. TRT in mL and TRT% in percentage
Total tumour burden repeatability for different tracer uptake intervals, reconstruction settings, and lesion delineation methods
| Method | 60 min of uptake | 90 min of uptake | ||||
|---|---|---|---|---|---|---|
| TRT (RC) | TRT% (RC%) | ICC | TRT (RC) | TRT% (RC%) | ICC | |
| EARL | ||||||
| SUV25 | 322 (1560) | 5.8 (56) | 0.95 | 59 (319) | 4.0 (18) | 1.00 |
| SUV40 | 236 (1149) | 3.7 (54) | 0.97 | 38 (252) | 8.4 (34) | 1.00 |
| 41MAX | 122 (611) | 8.9 (47) | 0.93 | 59 (169) | 3.1 (11) | 1.00 |
| A50P | 126 (667) | 7.6 (56) | 0.90 | 92 (287) | 9.7 (36) | 0.99 |
| MV2 | 257 (1133) | 9.4 (54) | 0.97 | 44 (257) | 4.1 (21) | 1.00 |
| MV3 | 96 (633) | 3.7 (48) | 0.93 | 91 (282) | 8.4 (35) | 0.99 |
| RD | 41 (505) | − 4.6 (43) | 0.99 | |||
| PSF | ||||||
| SUV25 | 309 (1069) | 9.1 (45) | 0.98 | 462 (2490) | 10.0 (41) | 0.93 |
| SUV40 | 133 (780) | 1.2 (39) | 0.99 | 41 (260) | 6.3 (26) | 1.00 |
| 41MAX | 65 (326) | 3.1 (38) | 0.98 | 83 (272) | 5.9 (22) | 0.99 |
| A50P | 60 (355) | − 1.2 (32) | 0.97 | 64 (182) | 8.6 (28) | 1.00 |
| MV2 | 138 (778) | 1.4 (42) | 0.99 | 70 (333) | 5.7 (24) | 1.00 |
| MV3 | 62 (322) | 0.8 (28) | 0.98 | 44 (115) | 4.5 (17) | 1.00 |
Average and repeatability coefficient of total tumour burden (TTB) repeatability for different tracer uptake intervals, reconstruction settings, and lesion delineation methods including the corresponding ICC. TRT in mL and TRT% in percentage